{"nctId":"NCT02265237","briefTitle":"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)","startDateStruct":{"date":"2014-10-28"},"conditions":["Hepatitis C Virus"],"count":184,"armGroups":[{"label":"Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir","Drug: ribavirin"]},{"label":"Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir","Drug: ribavirin"]},{"label":"Arm C","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir","Drug: ribavirin"]},{"label":"Arm D","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir","Drug: ribavirin"]}],"interventions":[{"name":"ombitasvir/paritaprevir/ritonavir","otherNames":["norvir (ritonavir)","paritaprevir (ABT-450)","ombitasvir (ABT-267)"]},{"name":"ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nFor Arms A, B and C:\n\n\\- Participants must meet one of the following:\n\n* Treatment-naive: Participant has never received antiviral treatment for hepatitis C infection OR\n* Treatment Experienced (Prior null responders, Partial responders or Relapsers to IFN/RBV);\n\nFor Arm D:\n\n\\- Participant must have prior treatment experience with SOF/pegIFN/RBV or SOF/RBV and meet one of the following categories:\n\n* Prior SOF breakthrough/non-responder: HCV RNA detectable at the end of treatment with SOF/pegIFN/RBV or SOF/RBV;\n* Prior SOF relapser: achieved HCV RNA undetectable at end of a prior treatment course SOF/pegIFN/RBV or SOF/RBV, but HCV RNA was detectable within 52 weeks following completion of therapy.\n\nFor Arms A, B, C and D:\n\n* Chronic HCV genotype 4 infection with cirrhosis.\n* Participant has plasma HCV RNA level \\> 1,000 IU/mL at Screening\n\nExclusion Criteria:\n\n* Positive test result at Screening for Hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).\n* Current enrollment in another interventional clinical study, previous enrollment in this study, or previous use of any protease inhibitor, non-nucleoside polymerase inhibitor, or Nonstructural viral protein (NS) 5A inhibitor, either investigational or commercially available (including previous exposure to paritaprevir or ombitasvir), or receipt of any investigational product within 6 weeks prior to study drug administration. Prior use of any direct-acting antiviral will not be allowed, except for Arm D where prior experience with the nucleoside polymerase inhibitor, sofosbuvir with pegIFN/RBV or SOF with RBV is required.\n* Any current or past clinical evidence of Child-Pugh B or C classification or clinical history of liver decompensation including ascites, variceal bleeding, or hepatic encephalopathy.\n* Confirmed presence of hepatocellular carcinoma.\n* Any cause of liver disease other than chronic HCV infection.\n* Abnormal laboratory tests.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants in Arms A, B and C With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (\\<LLOQ) 12 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":"97.5% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"93.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR12 in Participants Receiving 12 Weeks (Arm A) of Treatment Compared to Participants Receiving 16 Weeks of Treatment (Arm B)","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR12 in Participants Receiving 16 Weeks (Arm B) of Treatment Compared to Participants Receiving 24 Weeks of Treatment (Arm C)","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"93.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Arms A, B and C With On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \\< LLOQ during treatment; confirmed increase of \\> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or all on-treatment values of HCV RNA \\>= LLOQ with at least 6 weeks of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Arms A, B and C With Post-treatment Relapse","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants with HCV RNA levels \\< LLOQ at the end of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":60},"commonTop":["ASTHENIA","FATIGUE","HEADACHE","PRURITUS","ANAEMIA"]}}}